It's How Medicine Should Be®

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Roumen D. Balabanov, MD

Patient Feedback
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: Medical Academy, Sofia, Bulgaria
Residency: University of Chicago Medical Center - Neurology
Fellowship: University of Chicago Medical Center - Demyelinating Diseases
Clinical Expertise:
  • Autoimmune disorders
  • Central nervous system infections
  • Central nervous system vasculitis
  • Demyelinating diseases
  • Guillain-Barre syndrome
  • Multiple sclerosis
  • Myasthenia gravis
  • Transverse myelitis
Research Interests:
  • Autoimmune and demyelinating diseases of the nervous system
  • immunotherapy
Languages Spoken:
  • Bulgarian
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, Yaung K, Helenowski IB, Jovanovic B, Spahovic D, Arnautovic I, Lee DC, Benefield BC, Futterer S, Oliveira MC, Burman J
    2015 Jan 20
  2. Autoimmune Aquaporin-4 Myopathy in Neuromyelitis Optica Spectrum.
    Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, Lassmann H, Parisi JE, Pittock SJ, Stefoski D, Balabanov R, Lucchinetti CF
    JAMA Neurol
    2014 Jun 9
  3. Immunotherapy of neuromyelitis optica.
    Bienia B, Balabanov R
    Autoimmune Dis
  4. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.
    Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R.
    J Immunol. 2012
    2012 Nov 1
    189(9):4602-11. doi: 10.4049/jimmunol.1200486. Epub 2012 Sep 24.
  5. Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response'.
    Burt RK, Balabanov R, Voltarelli J, Barreira A, Burman J.
    Mult Scler. 2012
    2012 Jun
    18(6):772-5. doi: 10.1177/1352458512442993. No abstract available.
  6. Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination.
    Loda E, Balabanov R.
    Rev Neurosci. 2012
    2012 Jan 26
    23(2):145-52. doi: 10.1515/revneuro-2011-068. Review.
  7. Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Patel J, Balabanov R.
    Int J Mol Sci. 2012
    13(8):10647-59. doi: 10.3390/ijms130810647. Epub 2012 Aug 23.
  8. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Ko MY, Stefoski D, Balabanov R.
    Neurology. 2011
    2011 Sep 6
    77(10):1020; author reply 1020. doi: 10.1212/WNL.0b013e31822946d0. No abstract available.
  9. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R.
    J Neurosci. 2011
    2011 Jun 8
    31(23):8329-41. doi: 10.1523/JNEUROSCI.1028-11.2011.
  10. The CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival.
    Bonkowski D, Katyshev V, Balabanov RD, Borisov A, Dore-Duffy P.
    Fluids Barriers CNS. 2011
    2011 Jan 18
    8(1):8. doi: 10.1186/2045-8118-8-8.
  11. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination.
    Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R.
    J Neuroimmunol. 2011
    2011 Apr
    233(1-2):147-59. doi: 10.1016/j.jneuroim.2011.01.001. Epub 2011 Jan 22.
  12. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.
    Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V.
    J Neurol Sci. 2010
    2010 Mar 15
    290(1-2):16-21. doi: 10.1016/j.jns.2009.12.018. Epub 2010 Jan 12.
  13. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis.
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R.
    J Neuroimmune Pharmacol. 2010
    2010 Jun
    5(2):260-5. doi: 10.1007/s11481-010-9193-z. Epub 2010 Feb 23.
  14. STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells.
    Wang Y, Ren Z, Tao D, Tilwalli S, Goswami R, Balabanov R.
    Glia. 2010
    2010 Jan 15
    58(2):195-208. doi: 10.1002/glia.20912.
  15. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH.
    Lancet Neurol. 2009
    2009 Mar
    8(3):244-53. doi: 10.1016/S1474-4422(09)70017-1. Epub 2009 Jan 29. Erratum in: Lancet Neurol. 2009 Apr;8(4):309. Stefosky, Dusan [corrected to Stefoski, Dusan].
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.